- Home
- QCLS vs AYTU Comparison
QCLS vs AYTU Comparison
Compare QCLS & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QCLS | AYTU |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 27.4M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | QCLS | AYTU |
|---|---|---|
| Price | $3.82 | $2.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 342.8K | 30.1K |
| Earning Date | 04-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $2.50 | $1.20 |
| 52 Week High | $8.17 | $3.07 |
Technical Indicators
Market Signals| Indicator | QCLS | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 51.50 |
| Support Level | $3.38 | $2.46 |
| Resistance Level | $3.86 | $2.64 |
| Average True Range (ATR) | 0.28 | 0.10 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 41.91 | 75.81 |
Price Performance
Historical ComparisonAbout QCLS Q/C Technologies Inc.
Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.